JP2012518420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518420A5 JP2012518420A5 JP2011551315A JP2011551315A JP2012518420A5 JP 2012518420 A5 JP2012518420 A5 JP 2012518420A5 JP 2011551315 A JP2011551315 A JP 2011551315A JP 2011551315 A JP2011551315 A JP 2011551315A JP 2012518420 A5 JP2012518420 A5 JP 2012518420A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- residue
- polypeptide
- recombinant polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 18
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 210000001519 tissues Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000000926 neurological Effects 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
Claims (18)
- 配列番号2のアミノ酸残基1〜x 1 ("1b")を含む第1のセグメントと、配列番号5のアミノ酸残基x 1’ 〜x 2’ ("2a")を含む第2のセグメントを含むアミノ酸配列と少なくとも94%の配列同一性を有する組換えポリペプチドであって、ここで、x 1 は配列番号2の残基25、26、27、28、29、30、31、32、33、34、または35であり、x 1’ は配列番号5の残基22、23、24、25、26、27、28、29、30、31、または32であり、かつx 2’ は配列番号5の残基42、43、44、または45である前記組換えポリペプチド。
- 前記アミノ酸配列がさらに、配列番号2のアミノ酸残基x 2 〜x 3 ("3b")または配列番号5のアミノ酸残基x 2’ 〜x 3’ ("3a")を含む第3のセグメントを含み、ここで、x 2 は配列番号2の残基45、46、47、または48であり、x 3 は配列番号2の残基65、66、67、または68であり、かつx 3’ は配列番号5の残基61、62、63、または64である、請求項1に記載のポリペプチド。
- 配列番号16、18、22、24、26、28、30および32からなる群から選択される配列を含むポリヌクレオチド。
- 構築物1b2a3b4b5a6aを含む、請求項1に記載の組換えポリペプチド。
- 構築物1b2a3a4a5a6aを含む、請求項1に記載の組換えポリペプチド。
- 構築物1b2a3b4b5b6aを含む、請求項1に記載の組換えポリペプチド。
- 構築物1b2a3b4b5a6aを含む、請求項1に記載の組換えポリペプチド。
- 構築物1b2a3a4a5a6aを含む、請求項1に記載の組換えポリペプチド。
- 構築物1b2a3b4b5b6aを含む、請求項1に記載の組換えポリペプチド。
- 配列番号31に示される配列を含む、請求項1に記載の組換えポリペプチド。
- 配列番号17に示される配列を含む、請求項1に記載の組換えポリペプチド。
- 配列番号29に示される配列を含む、請求項1に記載の組換えポリペプチド。
- 前記アミノ酸配列がさらに、配列番号2のアミノ酸残基x 3 〜x 4 ("4b")または配列番号5のアミノ酸残基x 3’ 〜x 4’ ("4a")を含む第4のセグメントを含み、ここで、x 4 は配列番号2の残基76、77、78、79、80、81、または82であり、かつx 4’ は配列番号5の残基78、79、80、81、82、83、または84である、請求項2に記載のポリペプチド。
- 前記アミノ酸配列がさらに、配列番号2のアミノ酸残基x 4 〜x 5 ("5b")または配列番号5のアミノ酸残基x 4’ 〜x 5’ ("5a")を含む第5のセグメントを含み、ここで、x 5 は配列番号2の残基88、89、90、91、92、93、または94であり、かつx 5’ は配列番号5の残基90、91、92、93、94、95、または96である、請求項13に記載のポリペプチド。
- 前記アミノ酸配列がさらに、配列番号2のアミノ酸残基x 5 〜x 6 ("6b")または配列番号5のアミノ酸残基x 5’ 〜x 6’ ("6a")を含む第6のセグメントを含み、ここで、x 6 は配列番号2の残基112、113、または114であり、かつx 6’ は配列番号5の残基114、115、または116である、請求項14に記載のポリペプチド。
- 配列番号17、19、23、25、27、29、31、および33からなる群から選択される配列を含む、請求項1に記載のポリペプチド。
- 配列番号16、28、および30からなる群から選択される配列を含む、請求項1に記載のポリペプチド。
- 骨、軟骨、神経学的組織、心組織、骨格筋肉または内分泌組織に関連する疾患または障害を治療するための、請求項1に記載のポリペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15506609P | 2009-02-24 | 2009-02-24 | |
US61/155,066 | 2009-02-24 | ||
PCT/US2010/025260 WO2010099219A2 (en) | 2009-02-24 | 2010-02-24 | Designer ligands of tgf-beta superfamily |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012518420A JP2012518420A (ja) | 2012-08-16 |
JP2012518420A5 true JP2012518420A5 (ja) | 2013-04-04 |
JP5841845B2 JP5841845B2 (ja) | 2016-01-13 |
Family
ID=42666199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011551315A Active JP5841845B2 (ja) | 2009-02-24 | 2010-02-24 | TGF−βスーパーファミリーのデザイナーリガンド |
Country Status (6)
Country | Link |
---|---|
US (2) | US8952130B2 (ja) |
EP (1) | EP2401293B1 (ja) |
JP (1) | JP5841845B2 (ja) |
KR (1) | KR101558642B1 (ja) |
CA (1) | CA2752647A1 (ja) |
WO (1) | WO2010099219A2 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9688735B2 (en) * | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
EP2949338B1 (en) | 2010-08-20 | 2017-10-25 | Wyeth LLC | Designer osteogenic proteins |
EP2830646B1 (en) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
WO2014120619A2 (en) | 2013-01-30 | 2014-08-07 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
JP2016518357A (ja) | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨格筋幹細胞を若返らせる方法および組成物 |
US20160220640A1 (en) * | 2013-06-11 | 2016-08-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions for increasing neurogenesis and angiogenesis |
US20160287667A1 (en) * | 2013-11-08 | 2016-10-06 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating neuromuscular junctions |
CN106573966B (zh) | 2014-07-30 | 2022-03-01 | Ngm生物制药有限公司 | 用于治疗代谢异常的组合物和方法 |
EP3210144B1 (en) * | 2014-10-24 | 2020-10-21 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities |
MD20170035A2 (ro) | 2014-10-31 | 2017-09-30 | Ngm Biopharmaceuticals Inc | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
KR20170100634A (ko) | 2014-12-29 | 2017-09-04 | 바이오벤터스 엘엘씨 | 골 복구에서의 골유도 분자의 전달 향상을 위한 시스템 및 방법 |
JP2018527903A (ja) * | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | Gdf11結合タンパク質およびその使用 |
CN113896789A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
JP6948331B2 (ja) | 2016-01-06 | 2021-10-13 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する |
AU2017206069A1 (en) | 2016-01-08 | 2018-07-19 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
TWI815793B (zh) | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | 結合蛋白質及其使用方法 |
WO2017209519A1 (en) | 2016-05-31 | 2017-12-07 | Mogam Institute For Biomedical Research | Ab6 family designer ligands of tgf-beta superfamily |
WO2017209522A1 (en) * | 2016-05-31 | 2017-12-07 | Mogam Institute For Biomedical Research | Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating liver disease and use thereof |
WO2017209523A1 (en) * | 2016-05-31 | 2017-12-07 | Mogam Institute For Biomedical Research | Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating bone and cartilage disease and use thereof |
PT3368069T (pt) | 2016-06-13 | 2020-11-11 | Scholar Rock Inc | Uso de inibidores da miostatina e terapias de combinação |
CA3048735A1 (en) | 2016-12-30 | 2018-07-05 | Biogend Therapeutics Co., Ltd. | Recombinant polypeptides, compositions, and methods thereof |
EP4218817A3 (en) | 2017-01-06 | 2023-09-06 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
WO2018148649A1 (en) * | 2017-02-10 | 2018-08-16 | The Institute For Cancer Research D/B/A | Chimera of bone morphogenic protein 2 and the müllerian-inhibiting substance type ii receptor binding region of mullerian-inhibiting substance |
KR20240027854A (ko) | 2017-03-02 | 2024-03-04 | 내셔날 리서치 카운실 오브 캐나다 | Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도 |
EP3880695A4 (en) * | 2018-11-15 | 2022-01-19 | Joint Center For Biosciences | ACTIVIN/BMP7 CHIMERAS: SUPERACTIVE SAB704 AND SAB715, AND THEIR RESPECTIVE NOGGINE-SENSITIZED VARIANTS, NAB704 AND NAB715; AND NAB204 |
BR112022007749A2 (pt) | 2019-10-23 | 2022-07-05 | Cue Biopharma Inc | Construto de tgf-b, mascarado, complexo de tgf-b, heterodímero do complexo de tgf-b mascarado, um ou mais ácidos nucleicos, uso de um ou mais construtos ou complexos de tgf-b mascarados, composição, método de produção de um construto ou complexo de tgf-b mascarado e composição farmacêutica |
US20230416321A1 (en) * | 2020-11-23 | 2023-12-28 | Cue Biopharma, Inc. | TGF-Beta Polypeptides |
US11945856B2 (en) | 2022-01-28 | 2024-04-02 | 35Pharma Inc. | Activin receptor type IIB variants and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
US5106748A (en) * | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
US4877864A (en) * | 1987-03-26 | 1989-10-31 | Genetics Institute, Inc. | Osteoinductive factors |
US5108922A (en) * | 1986-07-01 | 1992-04-28 | Genetics Institute, Inc. | DNA sequences encoding BMP-1 products |
US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
ZA874681B (en) * | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
US5155058A (en) * | 1986-11-07 | 1992-10-13 | Canon Kabushiki Kaisha | Method of making semiconductor memory device |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
DK0448704T3 (da) | 1989-10-17 | 1999-04-06 | Stryker Corp | Osteogene anordninger |
AU8941791A (en) | 1990-10-18 | 1992-05-20 | Creative Biomolecules, Inc. | Osteogenic protein |
US5677196A (en) * | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US6333168B1 (en) * | 1993-05-20 | 2001-12-25 | The Trustees Of Columbia University In The City Of New York | Cloning, expression and uses of dorsalin-1 |
US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
US6300127B1 (en) * | 1997-07-30 | 2001-10-09 | Emory University | Bone mineralization proteins, DNA, vectors, expression systems |
US6846906B1 (en) * | 1998-10-07 | 2005-01-25 | Stryker Corporation | Modified proteins of the TGF-β superfamily, including morphogenic proteins |
US6677432B1 (en) | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
US20090042780A1 (en) * | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
WO2006047728A2 (en) * | 2004-10-27 | 2006-05-04 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Bmp gene and fusion protein |
-
2010
- 2010-02-24 KR KR1020117021911A patent/KR101558642B1/ko active IP Right Grant
- 2010-02-24 JP JP2011551315A patent/JP5841845B2/ja active Active
- 2010-02-24 CA CA2752647A patent/CA2752647A1/en active Pending
- 2010-02-24 WO PCT/US2010/025260 patent/WO2010099219A2/en active Application Filing
- 2010-02-24 US US12/712,069 patent/US8952130B2/en active Active
- 2010-02-24 EP EP10746779.7A patent/EP2401293B1/en active Active
-
2014
- 2014-12-30 US US14/586,573 patent/US20150239950A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012518420A5 (ja) | ||
JP2018138049A5 (ja) | ||
MX339277B (es) | Agente inductor de inmunidad. | |
BRPI0513143A (pt) | antagonistas de vla-4 multivalentes compreendendo porções poliméricas | |
JP2008508859A5 (ja) | ||
JP2012507271A5 (ja) | ||
RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
JP2010166916A5 (ja) | ||
JP2010519293A5 (ja) | ||
JP2010519931A5 (ja) | ||
JP2013107899A5 (ja) | ||
JP2010526153A5 (ja) | ||
EA201270713A1 (ru) | Белки на основе фибронектина с каркасными доменами, которые связывают ил-23 | |
JP2010519252A5 (ja) | ||
RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
BRPI0809594A2 (pt) | polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s) | |
JP2011507903A5 (ja) | ||
JP2012188436A5 (ja) | ||
JP2018531624A5 (ja) | ||
JP2018508530A5 (ja) | ||
JP2012505657A5 (ja) | ||
JP2009507474A5 (ja) | ||
RU2015119523A (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
JP2013531491A5 (ja) |